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Dietary nutrients have emerged as potential therapeutic adjuncts for inflammatory bowel
disease (IBD) given their impact on intestinal homeostasis through the modulation of
immune response, gut microbiota composition and epithelial barrier stability. Several
nutrients have already been associated with a protective phenotype. Yet, there is a
lack of knowledge toward the most promising ones as well as the most adequate
phase of action. To unveil the most prominent therapy candidates we characterized
the colon metabolic profile during colitis development. We have observed a twofold
decrease in threonine levels in mice subjected to DSS-induced colitis. We then assessed
the effect of threonine supplementation in the beginning of the inflammatory process
(DSS + Thr) or when inflammation is already established (DSS + Thr D8). Colitis
progression was similar between the treated groups and control colitic mice, yet
threonine had a surprisingly detrimental effect when administered in the beginning
of the disease, with mice displaying a delayed recovery when compared to control
mice and mice supplemented with threonine after day 8. Although no major changes
were found in their metabolic profile, DSS + Thr mice displayed altered expression in
mucin-encoding genes, as well as in goblet cell counts, unveiling an impaired ability to
produce mucus. Moreover, IL-22 secretion was decreased in DSS + Thr mice when
compared to DSS + Thr D8 mice. Overall, these results suggest that supplementation
with threonine during colitis induction impact goblet cell number and delays the recovery
period. This reinforces the importance of a deeper understanding regarding threonine
supplementation in IBD.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a complex debilitating
disorder of the gastrointestinal tract which comprises both
Crohn’s disease and ulcerative colitis. Despite the unclear etiology
of IBD, several factors have been accounted as key for the
development of the disease, such as genetics, immune system
and environmental factors, namely diet and gut microbiota
composition (Khor et al., 2011).
Dietary supplementation has emerged as a promising
therapeutic practice in the prevention and treatment of IBD
(Durchschein et al., 2016). Recent evidence has revealed
that fiber-enriched diets promote protection against IBD
development, since dietary fiber is mainly fermented by intestinal
microbiota into short-chain fatty acids (SCFAs), such as butyrate,
acetate and propionate (den Besten et al., 2013). The protective
properties of these metabolites are widely described by their
impact on immune cell activation and epithelial barrier stability
(Kelly et al., 2015; Macia et al., 2015), with decreased levels of
SCFAs being found in colon samples from IBD patients (Huda-
Faujan et al., 2010). Other studies have also pointed out several
specific amino acids that can improve intestinal homeostasis,
mainly by boosting mucosal healing and regeneration. For
instance, glutamine is known to promote protection in dextran
sulfate sodium (DSS)- and 2,4,6-trinitrobenzenesulfonic acid
(TBNS)-induced intestinal inflammation, acting via NF-κB
downregulation (Kretzmann et al., 2008). Colitic mice orally
administered with glutamine displayed suppressive Th1/Th17
immune responses and subsequently decreased inflammation
when compared to mice fed with regular diet (Hsiung et al., 2014).
Other amino acids have been also associated with a protective
phenotype against colitis. Using distinct animal models of colitis,
diets enriched in threonine, serine, proline and cysteine, given
before and throughout disease development, have been shown
to restore mucin synthesis and stabilization of gut microbiota
(Faure et al., 2006). Similar findings were observed with the
administration of a mixture of threonine, methionine and
monosodium glutamate after colitis induction (Liu et al., 2013).
Several studies have so far addressed whether administration
of specific nutrients may arise as a prophylactic and/or
therapeutic approach. However, there is a lack of knowledge
toward the most promising and adequate phase of action. Thus,
we investigated the metabolic profile of mice developing colitis,
aiming to identify variation of metabolites during inflammation.
The identification of the most attractive potential targets for
therapy and the definition of a time range more prone to
potentiate the effects of their supplementation may be relevant
for future applications in IBD prophylaxis and therapy.
MATERIALS AND METHODS
Animals
Seven to nine-week old C57BL/6J male mice were purchased
from Charles River Laboratories and housed in i3S animal
facilities, under pathogen free conditions, with food and water
ad libitum. All experimental procedures were approved by the
i3S Animal Ethics Committee and licensed by the Portuguese
National Authority for Animal Health (DGAV) with reference
014811/2016-07-13.
Colitis Induction
Dextran sulfate sodium (DSS; TdB Consultancy; 2% (w/v),
molecular weight approximately 40000 Da) was administered in
drinking water ad libitum for 5 days. Clinical signs of colitis
were monitored daily and scored as a disease activity index (DAI;
Supplementary Table S1).
L-Threonine Administration
Mice were divided into DSS (control), DSS with L-Threonine
(DSS+ Thr) and DSS followed by L-Threonine administration at
day 8 (DSS+ Thr D8), as shown in Figure 2A. L-Threonine [Thr;
Sigma–Aldrich; 0.166% (w/v) corresponding to 250 mg/Kg/day]
was given in the drinking water ad libitum. The dose was chosen
according to the daily intake in previous studies with rodents
(Faure et al., 2006; Liu et al., 2013) and to a high-threonine
human supplementation study (Pencharz et al., 2008). The safety
of our protocol measuring biomarkers of renal and liver damage
was evaluated to confirm the absence of toxicity (Supplementary
Figure S1). Similar fluid intake was found among all groups.
Metabolomic Analysis by Nuclear
Magnetic Resonance (NMR)
Methanol/water extracts of colon were analyzed at an
UltrashiedTM 800 Plus (Bruker) spectrometer as described
in Graça et al. (2017). Metabolite concentrations were performed
by integration of 1H-NMR resonances using TSP as reference.
Quantitative Real-Time PCR (qPCR)
Total RNA was isolated from colonic samples (TripleXtractor,
Grisp). As DSS inhibits both polymerase and reverse transcriptase
activities, RNA was purified with lithium chloride, as in Viennois
et al. (2013). qPCR was performed as described in Correia et al.
(2017). The list of primers used is in Supplementary Table S2.
Histology and Goblet Cell Count
Colons were fixed in 10% buffered formalin (Sigma–Aldrich)
and embedded in paraffin. Sections of 5 µm were stained with
hematoxylin/eosin and Alcian Blue/Periodic acid-Schiff. Goblet
cell number was assessed for each experimental condition in
a blinded fashion. Only crypts cut longitudinally from crypt
opening to bottom were analyzed.
Cytokine Quantification
Colonic explant cultures were performed as previously described
(McNamee et al., 2011). Cytokine quantification was performed
in supernatants by ELISA (Biolegend). Tissue explants were
homogenized and total protein was measured using Bradford
assay. The concentration of secreted cytokines in the supernatant
was normalized to total tissue protein and expressed as picogram
of cytokine per µg of total tissue protein.
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FIGURE 1 | Threonine levels in the colon decrease with intestinal inflammation. (A) Mice were treated with DSS to induce colitis and colon metabolites were
measured at day 0 and day 5 by NMR. (B) Partial least squares – discriminant analysis (PLS-DA) was obtained for samples of both days. (C) Top-five features
identified by the combination of the p-value from t-test analysis and magnitude of the change (fold change from day 5 versus day 0). (D) Important metabolites
selected by volcano plot with fold change threshold (x) 1.8 and t-test threshold (y) of 0.05. The purple circles represent features above the threshold. Both fold
changes and p-values are log transformed. (E) Threonine levels in the colon at day 0 and day 5. Data is shown as mean ± SD; n = 5 mice/group. One representative
experiment is shown out of two. ∗p < 0.05.
Statistical Analysis
Metabolite differences were evaluated by ANOVA in R statistical
software. Partial least squares – discriminant analysis (PLS-DA)
models were performed in SIMCA software. Other statistical
analyses were carried out with GraphPad Prism (version 6.01).
For multiple group comparisons one-way ANOVA test with
a Tukey multiple-comparison posttest was performed, while
for multiple group comparisons with repeated measures two-
way ANOVA test with a Tukey multiple-comparison posttest
was applied. Data are presented as mean ± standard deviation
(SD). Statistically significant values are: ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p< 0.001.
RESULTS AND DISCUSSION
To characterize the colon metabolic profile during colitis
development, metabolites present on colonic extracts of mice
prior (day 0) and after 5 days of DSS-induced colitis were
analyzed by NMR (Figure 1A). These time points were selected
since it allows the comparison of a homeostatic profile (day
0) against a period with established inflammation and lesion,
yet reversible and treatable (day 5). Multivariate analyses of
the metabolomic data only demonstrated minor alterations
between profiles for day 0 and day 5 of colitis development
(Figure 1B). However, univariate analyses performed on the
metabolites allow to discriminate ADP and particularly threonine
as significantly altered from day 0 to day 5 (Figures 1C,D).
Among essential amino acids, threonine has a prominent role
in maintaining a healthy gut. Threonine is able to generate
the main three SCFAs, namely acetate, butyrate and propionate
(Neis et al., 2015). In fact, it has been previously identified
several biosynthetic genes for threonine metabolism in the
human gut microbiota, suggesting the relevance of this amino
acid for microbiota biology (Abubucker et al., 2012). SCFAs are
described as important modulators of immune response, since
they are ligands for G-protein-coupled receptor 43 (GPR43)
that is expressed by immune cells on the lamina propria,
such as regulatory T cells, regulating the proinflammatory
responses in the intestine (Bollrath and Powrie, 2013). Moreover,
threonine is vastly metabolized in the intestine for mucin
synthesis (Faure et al., 2005). These proteins are paramount in
intestinal stability, since the mucus layer in the colonic outer
layer prevents the direct contact of luminal microorganisms
with the epithelium (Johansson et al., 2014). It has also been
suggested that threonine requirements are increased under
pathological settings to maintain proper intestinal function,
such as production and formation of the mucus layer (Remond
et al., 2009). Therefore, by participating in the mucus layer
synthesis and production of anti-inflammatory SCFAs, threonine
metabolism by gut microbiota proves to be essential for gut
barrier integrity and function. Our data show that threonine
levels drop 2-fold during colitis development until day 5
(Figures 1C–E). Therefore, we hypothesized that threonine
supplementation during active inflammatory disease could help
to restore the intestinal homeostasis and thus present some
therapeutic potential.
Previous studies have investigated threonine in combination
with other amino acids as a potential candidate for therapy
against colitis (Faure et al., 2006; Liu et al., 2013). Nevertheless,
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FIGURE 2 | Threonine supplementation on the onset of colitis development delays recovery and decreases goblet cell number. (A) Mice were supplemented with
threonine in the beginning of colitis induction (DSS + Thr) or after established inflammation (DSS + Thr D8). Mice treated only for colitis induction were used as
control (DSS). (B) Disease progression was assessed by scoring the disease activity index (DAI) throughout the experiment. (C) Quantification of short-chain fatty
acids (acetate, butyrate, propionate) and succinate by NMR was performed at day 13 of experiment. (D) Expression of mucin-encoding genes Muc1 and Muc2 was
performed by qPCR at day 13. (E) Colonic tissue sections were stained with Alcian Blue/periodic acid-Schiff. (F) Quantification of goblet cell number per crypt. Scale
bar = 50 µm. (G) IL-22 quantification on colonic explant cultures by ELISA. Data is shown as mean ± SD. n = 5 mice/group. One representative experiment is
shown out of two. The symbol ∗ corresponds to statistical differences between DSS + Thr and DSS; while # is related to statistical differences between DSS + Thr
and DSS + Thr D8. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
not only single threonine supplementation was not evaluated
before, but also there is scarce evidence regarding the most
adequate time frame for its supplementation in colitis treatment.
Accordingly, we addressed threonine supplementation in
two distinct phases: (1) in parallel with the initiation of
the inflammatory process, i.e., simultaneously with DSS
administration (DSS + Thr), and (2) on day 8, when
inflammation is already established (DSS + Thr D8). Mice
subjected to DSS-induced colitis but without threonine supply
were used as control (DSS) (Figure 2A). We observed that
the three groups developed colitis with a similar progression
profile. Nevertheless, after this time point, the recovery
profile of colitic mice supplemented with threonine in
the drinking water (DSS + Thr) was slower than that
of the other two groups, showing statistically significant
differences from day 10 to the final day of experiment when
compared to control group (DSS). Besides, DSS + Thr mice
had also a distinctive DAI score at day 11 and 12 when
compared with mice that only received threonine after
day 8 (DSS + Thr D8) (Figure 2B). Despite the divergent
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phenotype, no major differences were found in colon
length neither in the intestinal permeability (Supplementary
Figure S1).
Threonine administration was surprisingly detrimental for
disease recovery when given at the setting of the inflammatory
process. To understand this phenotype, we first evaluated the
potential alterations in the colon metabolic profile among
the different groups. No significant differences were found
between most of the metabolites. Particularly, the levels of the
major SCFAs (i.e., acetate, butyrate, and propionate), normally
associated with a protective phenotype, were similar among
groups. Only succinate levels, which is as an important marker
of inflammation promoting IL-1β induction in inflammatory
contexts (Tannahill et al., 2013), were found to be markedly
decreased in DSS + Thr D8 mice (Figure 2C). No major
alterations were observed in the inflammatory infiltrate profile,
tissue organization and hepatic and renal toxicity serum
biomarkers (Supplementary Figure S1).
Threonine plays a major role in mucin synthesis and
consequently in the formation of the mucus layer. Indeed, lack
of threonine is also known to impair intestinal paracellular
permeability and is associated with fewer goblet cells and mucus
synthesis (Faure et al., 2005; Mao et al., 2011). The mucus
layer serves as a barrier against microbial translocation to
the lamina propria and therefore its integrity is paramount
for intestinal homeostasis. When we analyzed the expression
of mucin-encoding genes, we found that Muc2 expression is
decreased in DSS + Thr mice when compared to mice that
only received threonine at day 8 (DSS + Thr D8) (Figure 2D).
Muc2 encodes for the oligomeric mucus gel-forming mucin 2
protein that is the major responsible for mucus synthesis. Indeed,
impairment or total absence of the mucus layer is associated with
severe colitis, as observed in Muc2-deficient mice (Van der Sluis
et al., 2006). We also found that DSS + Thr mice display higher
expression of Muc1, which has shown to contribute to intestinal
inflammation and colon cancer progression (Baldus et al., 2004;
Takahashi et al., 2015). We next quantified the number of goblet
cells of the colonic mucosa. These are a secretory epithelial
cell lineage found in both the small and the large intestines,
whose major function is the production of mucus. By analyzing
colon slices stained with Alcian Blue/Periodic acid-Schiff, we
observed that DSS + Thr mice displayed significantly fewer
goblet cells when compared to both DSS and DSS + Thr D8
(Figures 2E,F). Therefore, our results suggest that an alteration
in mucus synthesis due to threonine administration during the
onset of disease may impact intestinal integrity, by delaying the
recovery of disease. Faure et al. (2006) have demonstrated that
supplementation with diet containing higher doses of amino
acids, including L-threonine, lead to an increase in goblet
cell number, regulated mucin production in the colon and
restored microbiota composition after DSS treatment in rats.
Notwithstanding, not only the animal model is different, but also
L-threonine was given before colitis induction, which may be
underlying the distinctive outcome.
Previous studies have linked several cytokines to mucus
production in the intestine (Parks et al., 2015). To examine
the immunological profile of the three groups, cytokine levels
in the colon were quantified. No major changes were observed
between the groups for interleukin (IL)-1β, IL-12p70, IL-10,
IL-17A/F and granulocyte-macrophage colony-stimulating factor
(GM-CSF) levels (Supplementary Figure S2). Notwithstanding,
the amount of IL-22 was significantly decreased in DSS + Thr
mice when compared to DSS + Thr D8 mice (Figure 2G).
IL-22 is a member of the IL-10 family of cytokines and has
been vastly studied in the context of intestinal homeostasis.
It can be produced by several cell types, such as T helper
(Th1) 1, Th17, Th22 and innate lymphoid cells (ILCs), and
present several roles in the gastrointestinal tract, such as
tissue regeneration and maintenance of the intestinal epithelial
barrier (Rutz et al., 2013). Thus, the decreased IL-22 levels
may be associated with delayed recovery of the intestinal
balance.
Overall, our data demonstrate that supplementation of
threonine during colitis induction impairs goblet cell number,
with concomitant decreased Muc2 expression and IL-22
production. These variations are likely to be the cause of delayed
recovery observed in this situation. Interestingly, these effects
are not seen when threonine is administered once colitis is
established. Acute DSS-induced colitis is known to promote
gut microbial dysbiosis (Munyaka et al., 2016). Threonine is
metabolized by some intestinal commensal bacteria, leading
to the production of several metabolites used for intestinal
maintenance and to mediate immune responses (Neis et al.,
2015). Thus, threonine supplementation during induction of
colitis may impact differently the colonic microbiota populations
present during the onset and upon the establishment of
inflammation, having ultimately distinct effects in intestinal
function. Further understanding of the mechanisms underlying
threonine supplementation may give new insights on how dietary
nutrients modulate the dynamic balance between microbiome,
immune response and barrier function.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of European Council Directive (2010/63/EU)
guidelines that where transposed into Portuguese law (Decree-
Law n.◦113/2013, August 7th), i3S Animal Ethics Committee
and licensed by the Portuguese National Authority for Animal
Health (DGAV). The protocol was approved by the i3S
Animal Ethics Committee and licensed by the Portuguese
National Authority for Animal Health (DGAV) with reference
014811/2016-07-13.
AUTHOR CONTRIBUTIONS
JG, ET, CC, AgC, FR, MS, AnC, and RS designed the experiments.
JG, LG, RD-O, and RS performed the experiments. JG, LG, RD-O,
and RS analyzed the data. JG, LG, RD-O, and RS interpreted
the results. JG and RS drafted the manuscript and prepared the
tables and figures. JG, LG, RD-O, ET, CC, AgC, FR, MS, AnC,
and RS revised the paper and approved the final version of the
manuscript.
Frontiers in Physiology | www.frontiersin.org 5 September 2018 | Volume 9 | Article 1247
fphys-09-01247 September 4, 2018 Time: 9:42 # 6
Gaifem et al. Threonine Supplementation Effect in Colitis
FUNDING
This work was supported by the Northern Portugal Regional
Operational Programme (NORTE 2020), under the Portugal
2020 Partnership Agreement, through the European Regional
Development Fund (FEDER) (NORTE-01-0145-FEDER-
000013) and the Fundação para a Ciência e Tecnologia
(FCT) (contracts PD/BD/106053/2015 to JG via Inter-
University Doctoral Programme in Ageing and Chronic
Disease – PhDOC, IF/00021/2014 to RS, IF/01390/2014
to ET, IF/01147/2013 to RD-O, IF/00735/2014 to AgC,
SFRH/BPD/96176/2013 to CC, and SFRH/BPD/111100/2015
to LG). MS is a FCT investigator. The NMR data was
acquired at CERMAX (Centro de Ressonância Magnética
António Xavier) which is a member of the National NMR
network with the support of Project LISBOA-01-0145-FEDER-
007660.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fphys.
2018.01247/full#supplementary-material
REFERENCES
Abubucker, S., Segata, N., Goll, J., Schubert, A. M., Izard, J., Cantarel, B. L., et al.
(2012). Metabolic reconstruction for metagenomic data and its application to
the human microbiome. PLoS Comput. Biol. 8:e1002358. doi: 10.1371/journal.
pcbi.1002358
Baldus, S. E., Monig, S. P., Huxel, S., Landsberg, S., Hanisch, F. G., Engelmann, K.,
et al. (2004). MUC1 and nuclear beta-catenin are coexpressed at the
invasion front of colorectal carcinomas and are both correlated with tumor
prognosis. Clin. Cancer Res. 10, 2790–2796. doi: 10.1158/1078-0432.CCR-0
3-0163
Bollrath, J., and Powrie, F. (2013). Immunology. Feed your Tregs more fiber.
Science 341, 463–464. doi: 10.1126/science.1242674
Correia, C. R., Gaifem, J., Oliveira, M. B., Silvestre, R., and Mano, J. F. (2017). The
influence of surface modified poly(l-lactic acid) films on the differentiation of
human monocytes into macrophages. Biomater. Sci. 5, 551–560. doi: 10.1039/
c6bm00920d
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., and
Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between
diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340.
doi: 10.1194/jlr.R036012
Durchschein, F., Petritsch, W., and Hammer, H. F. (2016). Diet therapy
for inflammatory bowel diseases: the established and the new. World J.
Gastroenterol. 22, 2179–2194. doi: 10.3748/wjg.v22.i7.2179
Faure, M., Mettraux, C., Moennoz, D., Godin, J. P., Vuichoud, J., Rochat, F., et al.
(2006). Specific amino acids increase mucin synthesis and microbiota in dextran
sulfate sodium-treated rats. J. Nutr. 136, 1558–1564. doi: 10.1093/jn/136.6.
1558
Faure, M., Moennoz, D., Montigon, F., Mettraux, C., Breuille, D., and
Ballevre, O. (2005). Dietary threonine restriction specifically reduces intestinal
mucin synthesis in rats. J. Nutr. 135, 486–491. doi: 10.1093/jn/135.
3.486
Graça, G., Desterro, J., Sousa, J., Fonseca, C., Silveira, M., Serpa, J., et al. (2017).
Identification of putative biomarkers for leptomeningeal invasion in B-cell
non-Hodgkin lymphoma by NMR metabolomics. Metabolomics 13:136. doi:
10.1007/s11306-017-1269-9
Hsiung, Y. C., Liu, J. J., Hou, Y. C., Yeh, C. L., and Yeh, S. L. (2014). Effects of
dietary glutamine on the homeostasis of CD4+ T cells in mice with dextran
sulfate sodium-induced acute colitis. PLoS One 9:e84410. doi: 10.1371/journal.
pone.0084410
Huda-Faujan, N., Abdulamir, A. S., Fatimah, A. B., Anas, O. M., Shuhaimi, M.,
Yazid, A. M., et al. (2010). The impact of the level of the intestinal
short chain Fatty acids in inflammatory bowel disease patients versus
healthy subjects. Open Biochem. J. 4, 53–58. doi: 10.2174/1874091x010040
10053
Johansson, M. E., Gustafsson, J. K., Holmen-Larsson, J., Jabbar, K. S., Xia, L., Xu, H.,
et al. (2014). Bacteria penetrate the normally impenetrable inner colon mucus
layer in both murine colitis models and patients with ulcerative colitis. Gut 63,
281–291. doi: 10.1136/gutjnl-2012-303207
Kelly, C. J., Zheng, L., Campbell, E. L., Saeedi, B., Scholz, C. C., Bayless, A. J.,
et al. (2015). Crosstalk between microbiota-derived short-chain fatty acids and
intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17,
662–671. doi: 10.1016/j.chom.2015.03.005
Khor, B., Gardet, A., and Xavier, R. J. (2011). Genetics and pathogenesis of
inflammatory bowel disease. Nature 474, 307–317. doi: 10.1038/nature10209
Kretzmann, N. A., Fillmann, H., Mauriz, J. L., Marroni, C. A., Marroni, N.,
Gonzalez-Gallego, J., et al. (2008). Effects of glutamine on proinflammatory
gene expression and activation of nuclear factor kappa B and signal transducers
and activators of transcription in TNBS-induced colitis. Inflamm. Bowel Dis. 14,
1504–1513. doi: 10.1002/ibd.20543
Liu, X., Beaumont, M., Walker, F., Chaumontet, C., Andriamihaja, M.,
Matsumoto, H., et al. (2013). Beneficial effects of an amino acid mixture on
colonic mucosal healing in rats. Inflamm. Bowel Dis. 19, 2895–2905. doi: 10.
1097/01.MIB.0000435849.17263.c5
Macia, L., Tan, J., Vieira, A. T., Leach, K., Stanley, D., Luong, S., et al. (2015).
Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-
induced gut homeostasis through regulation of the inflammasome. Nat.
Commun. 6:6734. doi: 10.1038/ncomms7734
Mao, X., Zeng, X., Qiao, S., Wu, G., and Li, D. (2011). Specific roles of
threonine in intestinal mucosal integrity and barrier function. Front. Biosci. 3:
1192–1200.
McNamee, E. N., Masterson, J. C., Jedlicka, P., McManus, M., Grenz, A.,
Collins, C. B., et al. (2011). Interleukin 37 expression protects mice from
colitis. Proc. Natl. Acad. Sci. U.S.A. 108, 16711–16716. doi: 10.1073/pnas.11119
82108
Munyaka, P. M., Rabbi, M. F., Khafipour, E., and Ghia, J. E. (2016). Acute dextran
sulfate sodium (DSS)-induced colitis promotes gut microbial dysbiosis in mice.
J. Basic Microbiol. 56, 986–998. doi: 10.1002/jobm.201500726
Neis, E. P., Dejong, C. H., and Rensen, S. S. (2015). The role of microbial amino
acid metabolism in host metabolism. Nutrients 7, 2930–2946. doi: 10.3390/
nu7042930
Parks, O. B., Pociask, D. A., Hodzic, Z., Kolls, J. K., and Good, M. (2015).
Interleukin-22 signaling in the regulation of intestinal health and disease. Front.
Cell Dev. Biol. 3:85. doi: 10.3389/fcell.2015.00085
Pencharz, P. B., Elango, R., and Ball, R. O. (2008). An approach to defining the
upper safe limits of amino acid intake. J. Nutr. 138, 1996s–2002s. doi: 10.1093/
jn/138.10.1996S
Remond, D., Buffiere, C., Godin, J. P., Mirand, P. P., Obled, C., Papet, I., et al.
(2009). Intestinal inflammation increases gastrointestinal threonine uptake and
mucin synthesis in enterally fed minipigs. J. Nutr. 139, 720–726. doi: 10.3945/
jn.108.101675
Rutz, S., Eidenschenk, C., and Ouyang, W. (2013). IL-22, not simply a Th17
cytokine. Immunol. Rev. 252, 116–132. doi: 10.1111/imr.12027
Takahashi, H., Jin, C., Rajabi, H., Pitroda, S., Alam, M., Ahmad, R., et al. (2015).
MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene
34, 5187–5197. doi: 10.1038/onc.2014.442
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick,
A. F., Goel, G., et al. (2013). Succinate is an inflammatory signal that induces
IL-1beta through HIF-1alpha. Nature 496, 238–242. doi: 10.1038/nature
11986
Van der Sluis, M., De Koning, B. A., De Bruijn, A. C., Velcich, A., Meijerink, J. P.,
Van Goudoever, J. B., et al. (2006). Muc2-deficient mice spontaneously develop
Frontiers in Physiology | www.frontiersin.org 6 September 2018 | Volume 9 | Article 1247
fphys-09-01247 September 4, 2018 Time: 9:42 # 7
Gaifem et al. Threonine Supplementation Effect in Colitis
colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology
131, 117–129. doi: 10.1053/j.gastro.2006.04.020
Viennois, E., Chen, F., Laroui, H., Baker, M. T., and Merlin, D. (2013).
Dextran sodium sulfate inhibits the activities of both polymerase and reverse
transcriptase: lithium chloride purification, a rapid and efficient technique to
purify RNA. BMC Res. Notes 6:360. doi: 10.1186/1756-0500-6-360
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer DS and handling Editor declared their shared affiliation at the time of
the review.
Copyright © 2018 Gaifem, Gonçalves, Dinis-Oliveira, Cunha, Carvalho, Torrado,
Rodrigues, Saraiva, Castro and Silvestre. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 1247
